Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Letrozole|DRUG: Abemaciclib
Sponsor: University of Texas Southwestern Medical Center
Collaborators: Eli Lilly and Company|Cancer Prevention Research Institute of Texas